Beijing SL Pharmaceutical Co., Ltd. (002038-SZ) Stock Split, History Data
Working capital analysis
In terms of working capital, Beijing SL Pharmaceutical Co., Ltd. maintains a healthy position.
The total current assets of the company are valued at $2639981026.
This represents a growth rate of 32.153% compared to the previous year.
Breaking down the current assets, the cash and investments are worth $683831097, exhibiting a growth rate of 14.922% year-on-year.
The receivables, another significant portion of the current assets, are valued at $236213742.
The year-on-year growth rate for receivables is -41.877%.
The inventory, which forms a critical part of the assets, is valued at $144456874.
This represents a healthy year-on-year growth of 5.583%
On the liabilities side, the company's current liabilities total $373326272.
This reflects a growth rate of 29.254% over the previous year, indicating the company's financial obligations are well under control.
2023
2022
2021
2020
2019
2018
Cash and investments
683.83
595.04
827.84
663.48
1260.86
1166.20
Receavebles
236.21
406.41
533.95
649.93
841.24
847.51
Inventory
144.46
136.82
124.83
112.03
108.35
251.27
Other
126.29
714.51
648.74
608.08
514.44
508.53
Total Current Assets
2639.98
1997.67
2297.73
2207.34
2865.34
2803.16
Acc Payable
213.16
176.18
191.40
179.93
178.51
264.95
Short Term Debt
37.59
27.87
0.25
5.51
3.94
0.00
Other Current Liab
107.28
112.65
1.61
1.48
14.21
175.58
Current Liabilities
373.33
288.83
324.96
314.98
332.63
440.52
Capital Structure
When examining the capital structure of Beijing SL Pharmaceutical Co., Ltd., it is clear that the company manages a robust portfolio.
The value of their total assets clocks in at $6311959999.
When juxtaposed with the previous year, this marks a growth rate of 3.659%, showcasing the company's ability to steadily grow its asset base.
Turning to liabilities, the company has total liabilities amounting to $432246690.
Compared to the prior year, this reflects a growth rate of 6.326%.
Over the last year, the long-term debt has grown by -100.000%.
On the asset side, the cash and equivalent reserves are worth $643139595.
The year-on-year growth of these reserves is -8.500%.
The company's common stock, another important asset, holds a value of $1027349999, growing at a rate of -0.000% from the previous year.
Finally, the company's retained earnings stand at $4147899805, marking a growth rate of 4.593% year-over-year.
These earnings represent the profits that Beijing SL Pharmaceutical Co., Ltd. has chosen to reinvest in the business rather than distribute as dividends.
Total Assets
$6,311.96
Total liabilities
$432,246,690.00
Long term debt
$0.00
Cash and eqv
$643,139,595.00
Goodwill
$0.00
Retained earnings
$4,147,899,805.00
Common stock
$50.00
Enterprise Value
$27.12
Historical dividend key summary
Beijing SL Pharmaceutical Co., Ltd.'s dividend per share is $0.1, showing the earnings shared with shareholders per share. It has grown by 0.000% this year, suggesting that the company is generating increased income for shareholders and expecting future earnings growth.
Years
Q1
Q2
Q3
Q4
Total
2023
0.000
0.100
0.000
0.000
0.100
2022
0.000
0.100
0.000
0.000
0.100
2021
0.000
0.000
0.100
0.000
0.100
2020
0.000
0.000
0.200
0.000
0.200
2019
0.000
0.000
0.200
0.000
0.200
2018
0.000
0.333
0.000
0.000
0.333
2017
0.000
0.000
0.133
0.000
0.133
2016
0.000
0.000
0.133
0.000
0.133
2015
0.000
0.000
0.133
0.000
0.133
2014
0.000
0.000
0.089
0.000
0.089
2013
0.000
0.093
0.000
0.000
0.093
2012
0.000
0.000
0.074
0.000
0.074
2011
0.000
0.062
0.000
0.000
0.062
2010
0.000
0.049
0.000
0.000
0.049
2009
0.000
0.049
0.000
0.000
0.049
2008
0.000
0.012
0.000
0.000
0.012
2007
0.000
0.013
0.000
0.000
0.013
2006
0.000
0.008
0.000
0.000
0.008
2005
0.000
0.014
0.000
0.000
0.014
Net earnings per share (EPS)
Beijing SL Pharmaceutical Co., Ltd. has an EPS of $0.07, which signifies the profit allocated per share of common stock. With a growth rate of -83.215% this year, it indicates the company's increasing profitability and potential for share value growth. This trend signals robust financial performance and future potential.
Years
Q1
Q2
Q3
Q4
Total
2024
0.0683
-
-
-
0.07
2023
0.2
0.11
0.0004
0.0965
0.41
2022
0.0616
0.0993
0.0707
-0.0063
0.22
2021
0.09
0.21
0.13
0
0.43
2020
0.06
0.13
0.1
0.0599
0.35
2019
0.29
0.15
0.14
-0.0158
0.56
2018
0.18
0.16
0.18
0.0384
0.56
2017
0.12
0.1
0.15
0.14
0.51
2016
0.15
0.1
0.1
0.0926
0.44
2015
0.17
0.19
0.16
0.0575
0.58
2014
0.16
0.18
0.17
0.16
0.67
2013
0.13
0.16
0.14
0.13
0.56
2012
0.0956
0.12
0.12
0.13
0.47
2011
0.0733
0.27
0.0878
0.0823
0.51
2010
0.0551
0.077
0.0889
0.0754
0.31
2009
0.0464
0.0712
0.0706
0.054
0.24
2008
0.0341
0.0622
0.0635
0.0571
0.21
2007
0.0222
0.0454
0.0402
0.0416
0.15
2006
0.0091
0.017
0.021
0.0231
0.07
2005
0.0064
0.0134
0.0122
0.0089
0.04
2004
0.0083
0.0108
0.0094
0.0135
0.04
2003
-
-
0.0123
0.0146
0.02
Brief information
Beijing SL Pharmaceutical Co., Ltd. (002038.SZ) stock split history
Understanding the historical stock splits of Beijing SL Pharmaceutical Co., Ltd. (002038.SZ) provides insights into its past financial decisions and investor sentiment. A stock split occurs when a company increases its share count by dividing its existing shares. The most recent split took place on July 04, 2019 with a ratio of 1.5:1. Throughout its history, the company has undergone 7 stock splits. Below, we delve deeper into this history, highlighting past financial strategies.
